This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ballin, J. C. Articles by Warner, N. E. Search for Related Content PubMed PubMed Citation Articles by Ballin, J. C. Articles by Warner, N. E.

Clinical Evaluation of the Blood Cell Carboxypeptidase Inhibitor Test for Malignant Neoplasia

( U.S. Air Force Radiation Laboratory and the Department of Pharmacology, Biochemistry, and Pathology, University of Chicago,^* Chicago 37, Ill.)

The results of blood cell carboxypeptidase inhibitor (CPI) assays of the blood of 341 patients are reported. In normal persons and in cases of nonmalignant disease, the titer tends to be high, while in cases of malignant disease, the titer is greatly decreased. False positive results are observed chiefly in cirrhosis, pulmonary tuberculosis, and diabetes. False negative results are seen in 36 per cent of the malignant cases, chiefly carcinomas of the rectum and lung, malignant melanoma, lymphosarcoma, leukemia, and metastatic carcinoma of unknown primary site. All diseases tend to lower the CPI titer. The significance of this observation is discussed. The CPI test is not considered specific enough to be diagnostic for cancer.

^* This study was supported by funds provided under contract AF 33(038)27353 with the USAF School of Aviation Medicine, Randolph Field, Texas.

Received 6/10/53.